Zenas BioPharma, Inc.

ZBIO Nasdaq SEC CIK 1953926
Follow Zenas BioPharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $10M
Net income −$108.9M −111.5% vs same quarter last year
EPS, diluted −$1.65 −35.2% vs same quarter last year
Operating cash flow −$58M −41% vs same quarter last year
Revenue by quarter
$5M
$10M
$0
$0
$0
$1M
$10M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$10M−$377.7M
FY24$5M−$157M
FY23$50M−$37.1M
FY22--
MarginsShare of revenue
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−3830.6%−3777.4%
FY24−3277.8%−3139.8%
FY23−74.3%−74.2%
FY22--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$172.4M
FY24−$119.8M
FY23−$30.5M
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Zenas BioPharma
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY22FY23FY24FY25
Show the numbers
YearZenas BioPharmaHealthcare median
FY25−3777.4%−30.6%
FY24−3139.8%−47%
FY23−74.2%−58%
FY22-−80.4%